You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PTCL

Showing 1 - 25 of 258
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

First-line Maintenance Treatment of PTCL With Chidamide.

Recruiting
  • PTCL
  • Nanjing, Jiangsu, China
    Hematological Department, People's Hospital of Jiangsu Province
Jul 23, 2023

PTCL Patients Who Achieved Complete Response From Frontline Treatment Trial (Selinexor)

Not yet recruiting
  • PTCL Patients Who Achieved Complete Response From Frontline Treatment
  • (no location specified)
Apr 18, 2023

Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Trial (GFH009)

Not yet recruiting
  • Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
  • (no location specified)
Jun 28, 2023

Peripheral T Cell Lymphoma Trial in Zhengzhou (Golidocitinib, CHOP Regimen)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Jul 18, 2023

Newly Diagnosed Peripheral T-cell Lymphoma Trial in Nanjing (C-BEAM Regimen, BEAM Regimen)

Recruiting
  • Newly Diagnosed Peripheral T-cell Lymphoma
  • C-BEAM Regimen
  • BEAM Regimen
  • Nanjing, Jiangsu, China
    Hematological Department, People's Hospital of Jiangsu Province
Jun 27, 2023

Newly Diagnosed Peripheral T-cell Lymphoma Trial in Wuhan (Duvelisib, Chidamide)

Recruiting
  • Newly Diagnosed Peripheral T-cell Lymphoma
  • Duvelisib, Chidamide
  • Wuhan, Hubei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
Jul 27, 2023

Peripheral T-cell Lymphoma Targeted Therapy Trial in Tianjin (Azacitidine, Chidamide, Cyclophosphamide)

Enrolling by invitation
  • Peripheral T-cell Lymphoma Targeted Therapy
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Insititute & Hospital
Jan 9, 2023

Peripheral T-Cell Lymphoma (PTCL) Trial in Japan, Korea, Republic of (HBI-8000)

Completed
  • Peripheral T-Cell Lymphoma (PTCL)
  • Akita, Japan
  • +22 more
Jun 8, 2022

PTCL Trial in Long Beach, New Haven, Charlottesville (Azacytidine, Romidepsin, Belinostat)

Recruiting
  • PTCL
  • Long Beach, California
  • +2 more
Mar 1, 2022

HRAS Mutations or Peripheral T Cell Lymphoma (PTCL) Trial (Tipifarnib)

Available
  • HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)
  • (no location specified)
Jun 7, 2022

PI3Kd Inhibitor, Parsaclisib, CHOP Trial (Parsaclisib, CHOP)

Not yet recruiting
  • PI3Kδ Inhibitor
  • +3 more
  • (no location specified)
Feb 10, 2022

Allo-HSCT as First-line Consolidation in High-risk PTCL

Recruiting
  • T Cell Lymphoma
    • Beijing, China
      Peking University People's Hospital
    Jul 31, 2022

    Peripheral T Cell Lymphoma Trial in Harlingen (Belinostat Injection, Pralatrexate Injection, CHOP)

    Not yet recruiting
    • Peripheral T Cell Lymphoma
    • Belinostat Injection
    • +3 more
    • Harlingen, Texas
      Valley Cancer Associates
    Oct 16, 2023

    Peripheral T Cell Lymphoma Trial (CHOP+selinexor+5-Azacitidine, CHOP+duvelisib+5-Azacitidine, CHOP+chidamide+tislelizumab)

    Not yet recruiting
    • Peripheral T Cell Lymphoma
    • (no location specified)
    Dec 29, 2022

    Lymphatic Diseases Trial in Italy (Brentuximab Vedotin)

    Completed
    • Lymphatic Diseases
    • Brentuximab Vedotin
    • Bologna, Italy
    • +3 more
    Mar 21, 2022

    Relapsed or Refractory Peripheral T-cell Lymphoma Trial in Taiwan (Chidamide)

    Not yet recruiting
    • Relapsed or Refractory Peripheral T-cell Lymphoma
    • Kaohsiung, Taiwan
    • +4 more
    Apr 17, 2023

    Peripheral T Cell Lymphoma Trial in Shanghai (Azacitidine Injection, Dasatinib, Linperlisib)

    Recruiting
    • Peripheral T Cell Lymphoma
    • Azacitidine Injection
    • +6 more
    • Shanghai, Shanghai, China
      Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
    Nov 8, 2022

    Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma Trial (AFM13, AB-101, Cyclophosphamide)

    Not yet recruiting
    • Relapsed or Refractory Hodgkin Lymphoma
    • Peripheral T Cell Lymphoma
    • (no location specified)
    May 30, 2023

    Lymphoma Trial in China (Brentuximab Vedotin, Cyclophosphamide, Doxorubicin)

    Not yet recruiting
    • Lymphoma
    • Brentuximab Vedotin
    • +3 more
    • Beijing, China
    • +15 more
    Jan 4, 2023

    Refractory T-Cell Lymphoma, Relapsed T-Cell Lymphoma Trial in Italy (Daratumumab)

    Active, not recruiting
    • Refractory T-Cell Lymphoma
    • Relapsed T-Cell Lymphoma
    • Bari, Italy
    • +6 more
    Aug 1, 2022

    Peripheral T-Cell Lymphoma (PTCL) Trial in United States (Pralatrexate Injection)

    Completed
    • Peripheral T-Cell Lymphoma (PTCL)
    • Pralatrexate Injection
    • Rochester, Minnesota
    • +3 more
    Jul 23, 2021

    Peripheral T Cell Lymphoma Trial in Houston (Tenalisib)

    Withdrawn
    • Peripheral T Cell Lymphoma
    • Houston, Texas
      The University of Texas MD Anderson Cancer Center
    Oct 13, 2022

    Mature T-Cell and NK-Cell Tumor Trial in Hwasun-gun (Copanlisib, Gemcitabine)

    Completed
    • Mature T-Cell and NK-Cell Neoplasm
    • Hwasun-gun, Jeollanam-do, Korea, Republic of
      Chonnam National University Hwasun Hospital
    Jun 9, 2022

    Peripheral T/NK Cell Lymphoma (R/R PTCL) Trial (YY-20394)

    Recruiting
    • Peripheral T/NK Cell Lymphoma (R/R PTCL)
    • Houston, Texas
      MD Anderson Cancer Center
    Oct 19, 2022

    Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell Lymphoma Trial in Xiamen (Chidamide combined

    Recruiting
    • Peripheral T Cell Lymphoma
    • +2 more
    • Chidamide combined with Duvillisib
    • Xiamen, Fujian, China
      The First Affiliated Hosptial of Xiamen University
    Nov 28, 2023